Your browser doesn't support javascript.
loading
A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis.
Radeke, Heinfried H; Stein, Jürgen; Van Assche, Gert; Rogler, Gerhard; Lakatos, Peter L; Muellershausen, Florian; Moulin, Pierre; Jarvis, Philip; Colin, Laurence; Gergely, Peter; Kruis, Wolfgang.
Afiliación
  • Radeke HH; Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt am Main, Germany.
  • Stein J; Hospital of the Goethe University Frankfurt/Main, Frankfurt am Main, Germany.
  • Van Assche G; Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt am Main, Germany.
  • Rogler G; Translational Research in Gastrointestinal Disorders, School of Medicine, University of Leuven, Leuven, Belgium.
  • Lakatos PL; Clinic of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Muellershausen F; IBD Centre, Department of Medicine, McGill University, Montreal, Québec, Canada.
  • Moulin P; Novartis Basel, Basel, Switzerland.
  • Jarvis P; Novartis Basel, Basel, Switzerland.
  • Colin L; Novartis Basel, Basel, Switzerland.
  • Gergely P; Novartis Basel, Basel, Switzerland.
  • Kruis W; Novartis Basel, Basel, Switzerland.
Inflamm Intest Dis ; 5(4): 180-190, 2020 Nov.
Article en En | MEDLINE | ID: mdl-33313070
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Inflamm Intest Dis Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Inflamm Intest Dis Año: 2020 Tipo del documento: Article